Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case–control study

Liu, Shi Liang; Yang, Hong; Zhang, Peng; Zhang, Li; Zhao, Lei; Luo, Li; Fu, Jianhua; Liu, Meng Zhong; Xi, Mian

doi:10.1016/j.radonc.2015.07.020

Cited by 15 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of hematologic toxicity was increased in the cisplatin/vinorelbine regimen, but it was tolerable and manageable. 55 In subsequent years, a phase III trial of NEOCRTEC5010 was jointly conducted in patients with locally advanced ESCC from eight Chinese centers. The results of this trial demonstrated that survival in the NCRT group was significantly longer than that in the surgery-alone group; adverse events were acceptable and manageable.…”

Section: Current Consensus and Controversy On Surgery-based Multimodamentioning

confidence: 99%

“…The results of a randomized study comparing NCRT regimens, cisplatin/vinorelbine versus cisplatin/fluorouracil, in patients with locally advanced ESCC showed that the cisplatin/vinorelbine regimen achieved a higher pCR rate and a better survival than the cisplatin/fluorouracil regimen. The incidence of hematologic toxicity was increased in the cisplatin/vinorelbine regimen, but it was tolerable and manageable 55 . In subsequent years, a phase III trial of NEOCRTEC5010 was jointly conducted in patients with locally advanced ESCC from eight Chinese centers.…”

Section: Current Consensus and Controversy On Surgery‐based Multimodamentioning

confidence: 99%

See 1 more Smart Citation

Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma

Leng

Daiko²,

Han

et al. 2020

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide, especially in East Asia. ESCC accounts for more than 90% of esophageal cancer. Currently, neoadjuvant therapy in combination with surgical resection is the mainstay of treatment. However, the overall survival rate of patients with locally advanced ESCC is not satisfactory even when treated following the standard treatment guidelines. With neoadjuvant chemoradiotherapy, chemotherapy, or emerging immunotherapy, continuous exploration of efficacy in relation to ESCC is expected to improve overall survival further. Here, we review and summarize current evidence for efficacy of preoperative therapy for locally advanced ESCC.

show abstract

Section: Current Consensus and Controversy On Surgery-based Multimodamentioning

confidence: 99%

Section: Current Consensus and Controversy On Surgery‐based Multimodamentioning

confidence: 99%

Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma

Leng

Daiko²,

Han

et al. 2020

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…In recent years, many new regimens have shown promising effects for treating EC (3)(4)(5)(6)(9)(10)(11)(12)(13)(14). Of them, docetaxel is a frequently used taxane with cytotoxic activity against EC, especially esophageal squamous cell carcinoma (SCC).…”

Section: Introductionmentioning

confidence: 99%

Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy

Zhang

et al. 2017

Japanese Journal of Clinical Oncology

Self Cite

View full text Add to dashboard Cite

Objective: The optimal neoadjuvant chemoradiotherapy (CRT) regimen in esophageal cancer has not yet been defined. This study was aimed to compare the differences in pathologic response and survival between docetaxel/cisplatin and fluorouracil/cisplatin as neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (SCC). Methods: We retrospectively analyzed patients with thoracic esophageal SCC who received neoadjuvant CRT followed by esophagectomy from 2000 to 2014. After adjusting for sex, age, performance status, tumor length, tumor location and clinical TNM stage, 32 docetaxel/cisplatin-treated patients were matched to 62 patients who received fluorouracil/cisplatin at a ratio of 1:2. Treatment toxicity, pathologic complete response (pCR) and survival outcomes were compared between groups. Results: Baseline characteristics were well balanced between groups. The pCR rate in the docetaxel/cisplatin group was higher than that in the fluorouracil/cisplatin group but without significant difference (40.6% vs. 30.6%, P = 0.333). The 3-year overall survival rate in the docetaxel/cisplatin group was 64.9% versus 46.0% in the fluorouracil/cisplatin group (P = 0.039). There were no significant differences in incidence of treatment toxicity during CRT or surgical complications between groups, with the exception of Grade 3-4 hematologic toxicity (37.5% vs. 17.7%, P = 0.035), which was more frequent in the docetaxel/cisplatin group. Conclusions: Docetaxel/cisplatin might be associated with more favorable survival than fluorouracil/cisplatin in esophageal SCC treated with neoadjuvant CRT. Prospective validation is warranted.

show abstract

“…The grade 3/4 toxicities of patients in group B were akin to data reported previously. 13 – 15 For all patients, the most common toxicities were hematological toxicity and gastrointestinal reaction. Compared with previous studies, the grade 3/4 adverse effects of dCRT in the two groups were decreased, which was mainly attributed to the administration of antiemetic drugs before chemotherapy to decrease the incidence of gastrointestinal reaction.…”

Section: Resultsmentioning

confidence: 99%

Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients

Hu¹,

Wang²,

Wang³

et al. 2016

DDDT

View full text Add to dashboard Cite

BackgroundTo retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment.MethodsThis study retrospectively evaluated 202 patients with locally advanced ESCC treated at Shandong Cancer Hospital between January 2009 and December 2013. All the patients initially received dCRT, including platinum and paclitaxel or 5-fluorouracil, with concurrent 1.8 or 2 Gy/fraction radiation (total dose, 54–60 Gy). The patient population was divided into two treatment groups: 105 patients who received the cisplatinum/paclitaxel regimen were allocated to group A, and 97 patients who received the cisplatinum/5-fluorouracil regimen were allocated to group B. We compared the progression-free survival (PFS) and overall survival (OS) by various clinical variables, including prior treatment characteristics, major toxicities (mainly in grade 3 and 4 hematological), and response to dCRT. We used the receiver operating curve analysis to determine the optimal cutoff value of clinical stage and radiation dose. The Kaplan–Meier method was used for survival comparison and Cox regression for multivariate analysis.ResultsMedian PFS and OS in group A were significantly better compared with group B (median PFS, 15.9 versus 13.0 months, P=0.016 and median OS, 33.9 versus 23.1 months, P=0.014, respectively). The 1- and 2-year survival rates of the two groups were 82.9% versus 76.3%, and 61.9% versus 47.6%, respectively. The complete response and response rate were 17.1% versus 7.2% (P=0.032) and 52.4% versus 30.9% (P=0.042) in group A and B, respectively. Meanwhile, group B was associated with a significantly lower rate of grade 3/4 overall toxicity than group A (P=0.039).ConclusionOur data showed that patients with locally advanced ESCC in group A had longer PFS and OS compared with group B. Cisplatinum/paclitaxel can be considered a good candidate chemotherapy regimen for patients with locally advanced ESCC who are being treated with nonsurgical therapy.

show abstract

Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case–control study

Cited by 15 publications

References 21 publications

Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma

Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma

Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy

Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients

Contact Info

Product

Resources

About